Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,227.00GBp
26 May 2017
Change (% chg)

18.00 (+0.35%)
Prev Close
5,209.00
Open
5,225.00
Day's High
5,260.00
Day's Low
5,212.00
Volume
1,566,267
Avg. Vol
2,758,105
52-wk High
5,505.00
52-wk Low
3,680.00

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 0.97
Market Cap(Mil.): £59,284.27
Shares Outstanding(Mil.): 1,265.60
Dividend: 150.20
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 21.77 29.41 30.38
EPS (TTM): 2.15 -- --
ROI: 7.52 13.85 13.36
ROE: 20.99 14.79 14.50

BRIEF-AstraZeneca recalls one lot of Brilinta professional sample bottles

* Astrazeneca initiates voluntary nationwide recall of one lot of brilinta 90mg professional sample bottles due to report of another medicine in one bottle from that lot

May 25 2017

Drug approvals bounce back as R&D labs churn out new winners

LONDON The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.

May 25 2017

Drug approvals bounce back as R&D labs churn out new winners

LONDON, May 25 The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.

May 25 2017

AstraZeneca asthma shot hits goal but diabetes drug lags rival

LONDON AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

May 23 2017

AstraZeneca asthma shot hits goal but diabetes drug lags rival

LONDON AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

May 23 2017

UPDATE 1-AstraZeneca asthma shot hits goal but diabetes drug lags rival

* Bydureon fails to show heart risk reduction in diabetes (Wraps asthma and diabetes drug news)

May 23 2017

BRIEF-Genomic Vision to enter into technological collaboration with AstraZeneca in oncology

* GENOMIC VISION TO ENTER INTO TECHNOLOGICAL COLLABORATION WITH ASTRAZENECA IN ONCOLOGY

May 23 2017

BRIEF-Astrazeneca says Bydureon EXSCEL trial meets safety objective in diabetes patients

* Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk

May 23 2017

Severe asthma drug shows AstraZeneca promise beyond cancer

LONDON, May 22 AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

May 22 2017

AstraZeneca sells aging beta-blocker to Recordati for $300 million

LONDON AstraZeneca has sold the European rights to its aging beta-blocker heart drug Seloken to Italy's Recordati for $300 million, as part of a continuing drive by the British drugmaker to spin off non-core assets.

May 22 2017

More From Around the Web

Earnings vs. Estimates